Compare Home Depot Inc (HD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Sanofi SA — how do they compare? Home Depot Inc trades at $333.56 (market cap $332.08B), while Sanofi SA trades at $43.94 (market cap $104.83B). The key difference: Home Depot Inc is far larger — about 3.2× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| HD | SNY | |
|---|---|---|
Market Cap | $332.08B | $104.83B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $52.34 |
52-Week Low | $297.51 | $41.33 |
Enterprise Value | $393.64B | $121.32B |
Dividend Yield | 2.8% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $338.87, down 2.63% amid bearish technical signals and mixed fundamental performance. The stock shows strong profitability with 8.41% net margin and 128.38% ROE, but faces margin compression with profit margins declining from 10.87% in 2022 to 9.28% in 2025. Recent earnings show mixed results with Q3 2025 missing expectations while Q4 2025 and Q1 2026 beat estimates. Technical analysis indicates bearish momentum with key support at $321 and resistance at $343.
Despite near-term headwinds, HD maintains strong analyst support with 59% buy ratings and $370.59 consensus target, representing 9.4% upside. The company's robust cash flow generation and Pro business growth provide long-term stability, though rising mortgage rates and housing market sensitivity pose significant risks to near-term performance.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
